Cargando…
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease
O-Linked β-N-acetyl glucosaminylation (O-GlcNAcylation) is a dynamic post-translational modification that occurs on serine and threonine residues of cytosolic and nuclear proteins in all cell types, including those involved in the cardiovascular system. O-GlcNAcylation is thought to act in a manner...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932889/ https://www.ncbi.nlm.nih.gov/pubmed/20835337 http://dx.doi.org/10.4093/kdj.2010.34.4.211 |
_version_ | 1782186102049734656 |
---|---|
author | Karunakaran, Udayakumar Jeoung, Nam Ho |
author_facet | Karunakaran, Udayakumar Jeoung, Nam Ho |
author_sort | Karunakaran, Udayakumar |
collection | PubMed |
description | O-Linked β-N-acetyl glucosaminylation (O-GlcNAcylation) is a dynamic post-translational modification that occurs on serine and threonine residues of cytosolic and nuclear proteins in all cell types, including those involved in the cardiovascular system. O-GlcNAcylation is thought to act in a manner analogous to protein phosphorylation. O-GlcNAcylation rapidly cycles on/off proteins in a time scale similar to that for phosphorylation/dephosphorylation of proteins. Several studies indicate that O-GlcNAc might induce nuclear localization of some transcription factors and may affect their DNA binding activities. However, at the cellular level, it has been shown that O-GlcNAc levels increase in response to stress and augmentation of this response suppresses cell survival. Increased levels of O-GlcNAc have been implicated as a pathogenic contributor to glucose toxicity and insulin resistance, which are major hallmarks of type 2 diabetes and diabetes-related cardiovascular complications. Thus, O-GlcNAc and its metabolic functions are not yet well-understood; focusing on the role of O-GlcNAc in the cardiovascular system is a viable target for biomedical investigation. In this review, we summarize our current understanding of the role of O-GlcNAc on the regulation of cell function and survival in the cardiovascular system. |
format | Text |
id | pubmed-2932889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-29328892010-09-10 O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease Karunakaran, Udayakumar Jeoung, Nam Ho Korean Diabetes J Review O-Linked β-N-acetyl glucosaminylation (O-GlcNAcylation) is a dynamic post-translational modification that occurs on serine and threonine residues of cytosolic and nuclear proteins in all cell types, including those involved in the cardiovascular system. O-GlcNAcylation is thought to act in a manner analogous to protein phosphorylation. O-GlcNAcylation rapidly cycles on/off proteins in a time scale similar to that for phosphorylation/dephosphorylation of proteins. Several studies indicate that O-GlcNAc might induce nuclear localization of some transcription factors and may affect their DNA binding activities. However, at the cellular level, it has been shown that O-GlcNAc levels increase in response to stress and augmentation of this response suppresses cell survival. Increased levels of O-GlcNAc have been implicated as a pathogenic contributor to glucose toxicity and insulin resistance, which are major hallmarks of type 2 diabetes and diabetes-related cardiovascular complications. Thus, O-GlcNAc and its metabolic functions are not yet well-understood; focusing on the role of O-GlcNAc in the cardiovascular system is a viable target for biomedical investigation. In this review, we summarize our current understanding of the role of O-GlcNAc on the regulation of cell function and survival in the cardiovascular system. Korean Diabetes Association 2010-08 2010-08-31 /pmc/articles/PMC2932889/ /pubmed/20835337 http://dx.doi.org/10.4093/kdj.2010.34.4.211 Text en Copyright © 2010 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Karunakaran, Udayakumar Jeoung, Nam Ho O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title | O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title_full | O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title_fullStr | O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title_full_unstemmed | O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title_short | O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
title_sort | o-glcnac modification: friend or foe in diabetic cardiovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932889/ https://www.ncbi.nlm.nih.gov/pubmed/20835337 http://dx.doi.org/10.4093/kdj.2010.34.4.211 |
work_keys_str_mv | AT karunakaranudayakumar oglcnacmodificationfriendorfoeindiabeticcardiovasculardisease AT jeoungnamho oglcnacmodificationfriendorfoeindiabeticcardiovasculardisease |